Compare Huntington Ingalls Industries Inc (HII) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Novartis AG — how do they compare? Huntington Ingalls Industries Inc trades at $326.52 (market cap $12.92B), while Novartis AG trades at $152.79 (market cap $295.37B). The key difference: Novartis AG is far larger — about 22.9× Huntington Ingalls Industries Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| HII | NVS | |
|---|---|---|
Market Cap | $12.92B | $295.37B |
Sector | Technology | Health |
52-Week High | $453.73 | $168.62 |
52-Week Low | $265.40 | $119.31 |
Enterprise Value | $15.84B | $336.69B |
Dividend Yield | 1.68% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $324.38, down 1.94% on the day, with a bullish technical signal supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $5.27, exceeding expectations, and secured a $2.2 billion contract for surveillance capabilities (GlobeNewsWire, August 11, 2026). Valuation ratios include a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
Outlook remains positive due to contract wins and margin expansion, but risks include dependence on U.S. defense spending and competitive pressures. The consensus price target of $359.67 suggests upside potential, supported by 44% buy ratings from analysts.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
